Back to Search
Start Over
Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
- Source :
- Diabetes & Metabolism Journal, Vol 47, Iss 1, Pp 82-91 (2023)
- Publication Year :
- 2023
- Publisher :
- Korean Diabetes Association, 2023.
-
Abstract
- Background To evaluate the safety and effectiveness of empagliflozin in routine clinical settings, we collected and assessed the clinical profiles of Korean patients with type 2 diabetes mellitus. Methods This was a post-marketing surveillance study of empagliflozin 10 and 25 mg. Information on adverse events and adverse drug reactions (ADRs) was collected as safety data sets. Available effectiveness outcomes, including glycosylated hemoglobin (HbA1c) level, fasting plasma glucose, body weight, and blood pressure, were assessed. Results The incidence rate of ADRs was 5.14% in the safety dataset (n=3,231). Pollakiuria, pruritis genital, and weight loss were the most common ADRs. ADRs of special interest accounted for only 1.18%, and there were no serious events that led to mortality or hospitalization. In the effectiveness data set (n=2,567), empagliflozin significantly reduced the mean HbA1c level and body weight during the study period by –0.68%±1.39% and –1.91±3.37 kg (both P
Details
- Language :
- English
- ISSN :
- 22336079 and 22336087
- Volume :
- 47
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Diabetes & Metabolism Journal
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.6ea3f8d345114d5cab7609d0811df19b
- Document Type :
- article
- Full Text :
- https://doi.org/10.4093/dmj.2021.0356